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Abstract  27 
The metabolic syndrome is associated with an increase in the activation of renin angiotensin 28 
system (RAS) and inhibition of RAS reduces the incidence of new onset diabetes. Importantly, 29 
angiotensin II (AngII), independently of its vasoconstrictor action causes beta-cell 30 
inflammation and dysfunction, which may be an early step in the development of type-2 31 
diabetes. The aim of this study was to determine how AngII causes beta cell dysfunction. Islets 32 
of Langerhans were isolated from C57BL/6J mice that had been infused with AngII in the 33 
presence or absence of taurine-conjugated ursodeoxycholic acid (TUDCA) and effects on ER 34 
stress, inflammation and beta cell function determined. The mechanism of action of AngII was 35 
further investigated using isolated murine islets and clonal beta cells. 36 
We show that AngII triggers ER stress, an increase in the mRNA expression of pro-37 
inflammatory cytokines, and beta cell dysfunction in murine islets of Langerhans both in vivo 38 
and ex vivo. These effects were significantly attenuated by TUDCA, an inhibitor of ER stress. 39 
We also show that AngII-induced ER stress, is required for the increased expression of pro-40 
inflammatory cytokines and, is caused by ROS and IP3 receptor activation. 41 
These data reveal that the induction of ER stress is critical for AngII-induced beta cell 42 
dysfunction and indicates how therapies that promote ER homeostasis may be beneficial in the 43 
prevention of type-2 diabetes.  44 
 45 
Abbreviations: AngII (angiotensin II), 2APB (2-aminoethoxydiphenyl borate), AT1R 46 
(angiotensin type 1 receptor), ATF4 (activating transcription factor 4), CHOP (C/EBP 47 
Homologous Protein), ER (endoplasmic reticulum), GK (glucokinase), IRE1 (inositol 48 
requiring enzyme 1), PERK (PKR-like ER kinase), RAS (renin angiotensin system), TUDCA 49 
(taurine-conjugated ursodeoxycholic acid), UPR (unfolded protein response),   50 
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Introduction 51 
 52 
Elevated blood pressure due to increased activation of the renin angiotensin system (RAS) is 53 
an important feature of the metabolic syndrome. This constitutes a series of metabolic disorders 54 
that increase the risk of developing type-2 diabetes and cardiovascular disease. Importantly, 55 
the pharmacological inhibition of RAS reduces the incidence of new onset type-2 diabetes in 56 
high risk populations (1–3) and RAS blockade in several animal models of diabetes improves 57 
pancreatic beta cell function (4–8). Conversely, the infusion of AngII into mice causes beta 58 
cell dysfunction (9–11). As the components of the RAS system have been detected in islets and 59 
this ‘local’ RAS plays an important role in regulating islet mass and function (7,9), the effects 60 
of RAS blockade in vivo is likely mediated by inhibiting locally produced AngII.  61 
 62 
The detrimental effects of AngII on beta cell function were largely attributed to 63 
vasoconstriction resulting in decreased delivery of glucose to pancreatic beta cells (12–14). 64 
However, it has recently been shown that AngII infusion in mice causes beta cell dysfunction 65 
independently of AngII’s effect on blood pressure (11). In support of this, the treatment of 66 
either isolated human or rodent islets with AngII also causes beta cell dysfunction (9–11). The 67 
damaging effects of AngII on beta cell function, both in vivo and in vitro, have been ascribed 68 
to an increase in the expression of pro-inflammatory cytokines, in particular IL-1β (11), and 69 
there is a growing body of evidence indicating that inflammation is important in the 70 
development of beta cell dysfunction in type-2 diabetes (15–17). Endoplasmic reticulum (ER) 71 
stress is also associated with the loss of beta cell function and viability in type-2 diabetes (18–72 
21). This stress is sensed by the ER transmembrane proteins: PKR-like ER kinase (PERK), 73 
activating transcription factor 6 (ATF6) and inositol requiring enzyme 1α (IRE1) that activate 74 
an adaptive response called the unfolded protein response (UPR) (21–23). If the UPR is unable 75 
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to alleviate ER stress beta cell dysfunction and death can occur through the chronic activation 76 
of a UPR, which activates a number of pro-apoptotic and pro-inflammatory signaling pathways 77 
(16,23,24). Given that AngII also increases the expression of pro-inflammatory cytokines and 78 
causes beta cell dysfunction (11), we hypothesised that ER stress may play an important role 79 
in AngII-mediated beta cell inflammation and dysfunction.  80 
 81 
 82 
Materials and Methods 83 
Cell culture. Mouse insulinoma 6 (MIN6) cells (25) were used between passages 25 and 35 at 84 
~80% confluence and cultured as previously described (26).  85 
 86 
Islet isolation. Pancreatic islets were isolated from adult C57BL/6J mice (Animal Resources 87 
Centre, Perth, Australia)). Briefly the pancreas was inflated by injecting 3 ml of RPMI 1640 88 
(Invitrogen) containing 1mg/ml collagenase (Sigma-Aldrich, Australia) through the common 89 
pancreatic duct and the pancreas excised.  Islets were then isolated  as previously described 90 
(26). 91 
 92 
Animal experimentation. All experiments were approved by the Animal Ethics Committee of 93 
RMIT University (#1504). Male C57BL/6J mice (10 weeks of age) obtained from the Animal 94 
Resources Centre (Perth, Australia) were kept at 22±1°C on a 12-h light/dark cycle. All mice 95 
were fed standard mouse chow and water ad libitum. After 1 week of acclimatization, the mice 96 
were randomly assigned to 3 groups: 1) sham (control mice infused with PBS, n=8); AngII 97 
(mice infused with human AngII, dissolved in sterile 1XPBS, at 416ng.kg-1.min-1 using 98 
subcutaneous ALZET® mini-osmotic pumps (USA) for 2 weeks, n=8); or AT (mice infused 99 
with AngII with daily intra-peritoneal injection of TUDCA at 150 mg.kg-1.day-1 for 2 weeks, 100 
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n=8). Human Ang II (≥93%HPLC) was purchased from Sigma. The body weight and plasma 101 
glucose levels were recorded three times weekly during the experiment. Systolic blood pressure 102 
(SBP) was measured using the CODA tail-cuff blood pressure system (ADInstruments Pty 103 
Ltd., Australia). 104 
For Glucose tolerance tests (GTT; 2.5 g glucose/kg BW, ip) mice were fasted for 5 h 105 
prior to blood samples being collected via the tail vein and blood glucose concentration 106 
determined using a glucometer (AccuCheck Proforma Nano; Roche, Victoria, Australia). For 107 
insulin measurements blood samples were centrifuged (2000 rpm, 2 min at 4oC) and the plasma 108 
insulin concentrations measured by ELISA (Linco Research, St. Louis, MO) in collaboration 109 
with the Department of Physiology, Monash University, Melbourne. Mice were euthanized 110 
with CO2. The disposition index, a composite measure of beta cell function (27), was also 111 
calculated using the following formula: ∆I0-30/∆G0-30 × 1/fasting insulin.  112 
 113 
Western-blotting and Immunohistochemistry. SDS-PAGE and western blotting were 114 
performed as previously described (28) using antibodies against: BiP (BD Transduction 115 
Laboratories, USA), phospho-IRE1α (Ser 724) (Abcam, USA), phospho-PERK (Thr 980), 116 
phospho-eIF2α (Ser 51), CHOP, ATF4, and GAPDH (Cell Signaling Technology, USA). 117 
Immunohistochemistry was performed on fixed and paraffin embedded pancreatic sections 118 
using anti-CHOP, and Alexa Fluor 488 conjugated antibodies. All antibodies were used as per 119 
manufacturer’s instructions.  120 
  121 
Transfection, RNA isolation and qPCR analyses. Silencer® Select siRNAs against Ire (cat. no. 122 
S95857) and Xbp (cat. no. S76114) were purchased from from Ambion®oligos (Thermo 123 
Scientific, USA).siRNA oligos were tranfected using Lipofectamine® RNAiMAX (Thermo 124 
Scientific, USA) according to the manufacturer’s protocol. Total RNA was isolated using the 125 
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ReliaPrep™ RNA Cell Miniprep System (Promega, USA). Reverse transcription was carried 126 
out using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, UK). 127 
Quantitative PCR was carried out using the SYBR® Green PCR Master Mix (Applied 128 
Biosystems, UK) using primers described in ESM Table 1. The gene expression from each 129 
sample was analysed in duplicate and normalized against the housekeeper 18S. All reactions 130 
were performed on the Rotor-Gene Q (Qiagen, USA). The results are expressed as relative 131 
gene expression using the ΔCt method (29). 132 
 133 
Glucose stimulated insulin secretion (GSIS). Isolated islets were cultured overnight in RPMI 134 
1640 medium supplemented with L-glutamine (20 mmol/l), and FBS (5%). GSIS was 135 
performed as previously described (28). Insulin ELISA was performed as described above. 136 
 137 
Quantification of superoxide levels Superoxide levels were measured using L-012 (Tocris 138 
Bioscience, USA) enhanced chemiluminescence as previously described (30). MIN6 cells were 139 
plated on a 96-well Optiplate (PerkinElmer, Melbourne, Australia), incubated with 100 µmol/L 140 
L-012, and luminescence measured using a BMG Clariostar plate reader (BMG Labtech, 141 
Melbourne, Australia).  142 
 143 
Statistical analysis Data are expressed as mean ± SE, unless otherwise stated. Data were 144 
analysed by one-way ANOVA followed by Tukey’s post-hoc test for multiple comparison 145 
between means using Prism 6 (GraphPad Software, USA). Differences were considered 146 
statistically significant at p < 0.05. 147 
 148 
Results 149 
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Angiotensin II induces ER stress and impairs beta cell function in mouse islets of Langerhans. 150 
To investigate the role of ER stress on AngII-dependent beta cell dysfunction, mouse islets of 151 
Langerhans were treated with AngII for 96 h in the presence or absence of TUDCA, a chemical 152 
chaperone that inhibits ER stress (31). AngII caused beta cell dysfunction as demonstrated by 153 
a marked increase of basal insulin secretion and significant decrease in the stimulatory index 154 
compared to control islets reflecting the loss of the glucose-stimulated insulin secretion (GSIS) 155 
(Fig. 1a and b). This correlated with a decrease in the mRNA expression of glucokinase (Gk) 156 
(Fig. 1c), whereas the mRNA expression of glucose transporter-2 (Glut-2) and pancreatic and 157 
duodenal homeobox 1 (Pdx1) were increased (Fig 1c). AngII treatment also significantly 158 
increased the expression of the pro-inflammatory cytokines interleukin 1β (Il-1β) and tumor 159 
necrosis factor α (Tnf-α) (Fig. 1d). However, no significant changes in monocyte chemotactic 160 
protein 1 (Mcp-1) were detected. Importantly, AngII caused a marked increase in the 161 
expression of markers of ER stress (Fig. 1e), including immunoglobulin binding protein 162 
(BiP/Grp78), the spliced form of X-box binding protein 1 (Xbp1s), endoplasmic reticulum 163 
oxidoreductin 1 (Ero1l), peptidyl-prolyl cis-trans isomerase (Fkbp11), ER degradation 164 
enhancing α-mannosidase-like protein (Edem), activating transcription factor 4 (Atf4) and the 165 
pro-apoptotic transcription factor C/EBP Homologous Protein (Chop also known as Gadd153) 166 
(32,33). The co-administration of TUDCA with AngII significantly restored beta cell function, 167 
as demonstrated by a reduction in basal insulin secretion (Fig. 1a), an improved stimulatory 168 
index (Fig. 1b) and the restoration of glucokinase expression to control levels (Fig 1c). TUDCA 169 
also significantly decreased the expression of the pro-inflammatory cytokines Il-1β and Tnf-α 170 
(Fig 1d) and all the markers of ER stress investigated (Fig. 1e). Thus AngII causes beta cell 171 
dysfunction, ER stress and inflammation in mouse islets of Langerhans and these effects occur 172 
independently of AngII’s systemic vasoconstrictive effects. Moreover, as TUDCA counteracts 173 
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the effects of AngII it is likely that the deleterious effects of AngII treatment observed here are 174 
mediated through ER stress. 175 
 176 
ER stress precedes the induction of pro-inflammatory cytokines in AngII treated MIN6 cells 177 
and Islets of Langerhans.  We initially investigated the efficacy of using the pancreatic beta 178 
cell line MIN6 as a model to further investigate AngII-induced-ER stress and inflammation. 179 
MIN6 cells were treated with AngII or thapsigargin, a pharmacological inducer of ER stress, 180 
in the presence or absence of TUDCA (ESM Fig 1). As observed in islets, AngII treatment 181 
caused ER stress and an increase in the expression of Il-1β, which was inhibited by TUDCA. 182 
Thapsigargin also evoked a UPR and increased the expression of Il-1β.  183 
To investigate the temporal relationship between AngII-induced ER stress and the expression 184 
of pro-inflammatory cytokines, MIN6 cells were treated with AngII for up to 96 h and the 185 
induction of ER stress and the expression of Il-1β, Tnf-α and Mcp-1 were monitored. AngII 186 
rapidly induced ER stress (within 2 h) as determined by the phosphorylation status of: IRE1α, 187 
PERK, PERK’s substrate eIF2α, and an increase in the expression of BiP, ATF4 and CHOP 188 
and Xbp1s, (Fig. 2a and b). AngII increased the expression of thioredoxin interacting protein 189 
(TXNIP) (16) (Fig. 2b) at 6h and the expression of the pro-inflammatory cytokine Il-1β and 190 
Tnf-α mRNA by 6 h and 48 h respectively (Fig. 2c).  No changes in the expression of Mcp1 191 
were detected (Fig. 2c). AngII treatment of mouse islets caused an increased in the expression 192 
of Xbp1s, Atf4 and Chop which preceded an increase in the expression of Il-1β and Tnfα (Fig 193 
2d).  194 
Therefore, the occurrence of ER stress precedes an increase in the expression of the pro-195 
inflammatory cytokines providing evidence that AngII-induced ER stress may promote 196 
inflammation in beta cells.  197 
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 198 
The role of PERK and IRE1α in AngII-induced expression of the pro-inflammatory cytokines. 199 
To determine how ER stress increases the expression of the pro-inflammatory cytokines, we 200 
investigated the effect of a selective inhibitor of PERK (GSK2606414 (PERKi)) and siRNA 201 
mediated knock-down of Ire1α or Xbp1 on AngII-induced Il-1β expression. GSK2606414 202 
inhibited AngII-induced phosphorylation of eIF2α (Fig. 3a) and expression of ATF4, CHOP 203 
(Fig. 3a), Txnip (Fig. 3b) and importantly Il-1β (Fig. 3b). As anticipated siRNAs directed 204 
towards Ire1α or Xbp1 significantly reduced Xbp1s basal expression and AngII induced 205 
increases in Xbp1s expression (Fig. 3c). Importantly, siRNA-mediated knock-down of Ire1α 206 
or Xbp1 also inhibited AngII evoked increases in Txnip and Il-1β expression (Fig. 3d). These 207 
results provide evidence that both PERK and IRE1α are required for Ang II to induce a pro-208 
inflammatory response. 209 
 210 
Angiotensin-II induced ER stress is dependent upon both IP3R and NOX activation. AngII-211 
induced ER stress and inflammation is dependent on AT1R activation as irbesartan (IRB), an 212 
angiotensin 1 receptor (AT1R) antagonist, attenuated both AngII-induced ER stress and Il-1β 213 
expression (ESM Fig. 2). The AT1R classically couples to Gq/11 and activates NADPH 214 
oxidase (NOX) and phospholipase-C (PLC) resulting in an increase in IP3 and ROS (34,35). 215 
IP3 stimulates ER calcium release (34) and ROS has been shown to sensitise the IP3 receptor 216 
(IP3R) (36). As a decrease in ER calcium can induce ER stress (26) we investigated whether 217 
the effects of AngII were mediated by an IP3R-dependent mechanism. MIN6 cells were treated 218 
with AngII in the presence or absence of selective IP3 receptor antagonists, 2-219 
aminoethoxydiphenyl borate (2APB) and xestospongin-C (XestC). 2APB and Xest-C inhibited 220 
AngII-induced ER stress as determined by a significant decrease in eIF2α phosphorylation, as 221 
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well as the expression of ATF4 and CHOP (Fig. 4a). Therefore, AngII-induced ER stress 222 
requires IP3R activation indicating that AngII-induced ER stress is likely to be mediated by a 223 
decrease in ER calcium. However, for reasons which are unclear, at 6h treatment of cells with 224 
AngII in the presence of xestospongin-C potentiated AngII-induced eIF2α phosphorylation 225 
(Fig. 4a).  226 
To investigate the role of ROS, changes in superoxide production in MIN6 cells in response to 227 
AngII in the presence or absence of the AT1R antagonist irbesartan, and two selective 228 
inhibitors of NOX, apocyin and  diphenyleneiodonium (DPI) was determined (Fig. 4b). As 229 
anticipated AngII increased superoxide levels and this was inhibited by apocynin (at 10 and 230 
300 μM), DPI and irbesartan (Fig. 4b). Importantly, apocynin or DPI also inhibited AngII-231 
induced ER stress as determined by the phosphorylation of eIF2α and the expression of ATF4 232 
and CHOP (Fig. 4c). These data provide evidence that ROS is required for AngII-induced ER 233 
stress. Given that IP3R activation is also required, it is possible that ROS promotes ER stress 234 
by sensitizing the IP3R (36).  235 
High glucose potentiates AngII-induced ER stress. To investigated the effect of glucose 236 
concentration on AngII-induced ER stress. MIN6 cells were incubated at either low (5.5mM) 237 
glucose or high (25mM) glucose and the effect of AngII on ER stress determined. AngII 238 
treatment of MIN6 cells incubated at low glucose caused a significant increase in the 239 
expression of CHOP and ATF4 which marks the presence of ER stress. Interesting, incubation 240 
at high glucose (25mM) potentiated the effect of AngII on ER stress (ESM Fig 3a).  These 241 
experiments were repeated using isolated murine islets and similar results were obtained (ESM 242 
Fig 3b). Thus, high glucose potentiates the effects of AngII on ER stress. 243 
 244 
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Angiotensin II infusion of mice causes ER stress and an increase in the expression of pro-245 
inflammatory cytokines in pancreatic islets. To assess whether a chronic elevation in AngII 246 
caused ER stress in islets in vivo and whether this was important in the induction of pro-247 
inflammatory cytokines, mice were infused with AngII for 2 weeks with or without the co-248 
administration of TUDCA. Following AngII infusion, mice displayed a marked impairment of 249 
glucose tolerance (Fig. 5a, b) together with elevated levels of fasting plasma insulin (Fig. 5c), 250 
likely due to the known detrimental effects of AngII on insulin sensitivity (37). Interestingly, 251 
there was also evidence of beta cell dysfunction as determined by a decrease in the disposition 252 
index (Fig. 5d). The co-administration of TUDCA improved glucose tolerance, reduced plasma 253 
insulin levels (Fig. 5a and c) and rescued beta cell function (Fig. 5d). All these effects occurred 254 
independently of changes in body weight, adiposity, or a sustained increase in systolic blood 255 
pressure (SBP;ESM Fig 4). Importantly, islets isolated from these AngII infused animals 256 
showed signs of ER stress as evidenced by an increase in the expression of Xbp1s, Fkbp11, 257 
Ero1l, Edem, Atf4 and Chop and Txnip (Fig. 5e). Although no change in the expression of BiP, 258 
an adaptive marker of the UPR, was detected (Fig. 5e). Importantly, Il-1β and Tnf-α, expression 259 
were also augmented by AngII infusion (Fig. 5f). Interestingly, as observed in isolated islets, 260 
AngII caused an increase in Pdx1 and Glut2 expression but a decrease in glucokinase 261 
expression (Fig. 5g). The co-administration of TUDCA inhibited AngII-stimulated increase in 262 
the expression of markers of ER stress (Fig. 5e), the pro-inflammatory cytokines (Fig. 5f) and 263 
the markers of beta-cell function (Fig. 5g). Taken together, these data provide evidence that in 264 
vivo AngII causes ER stress and that this increases the production of pro-inflammatory 265 
cytokines in islets.  266 
To determine whether macrophages were present in islets isolated from AngII treated mice we 267 
looked for the presence of F4/80, a macrophage specific marker, by qPCR (ESM Fig. 5). 268 
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Although F4/80 mRNA was detected in islets its expression was unchanged by AngII indicating 269 
the macrophages are unlikely to be the source of the pro-inflammatory cytokines. 270 
    271 
Discussion 272 
This study provides strong evidence that AngII causes ER stress to beta cells/islets both in vitro 273 
and in vivo and that this results in a pro-inflammatory phenotype and beta cell dysfunction. In 274 
addition, we provide a novel insight into how AngII causes ER stress (Fig. 6). We show that at 275 
high glucose AngII, via AT1R activation, promotes IP3R activation and an increase in ROS. 276 
This, likely via a decrease in ER calcium, results in ER stress and an increase in the expression 277 
of pro-inflammatory cytokines mediated by the activation of PERK and IRE1α.  278 
Although inflammation and the UPR are protective responses, chronic inflammation and/or 279 
UPR activation is associated with the pathogenesis of many diseases including type-2 diabetes 280 
(23). Indeed chronic inflammation has been implicated in beta cell dysfunction in type-2 281 
diabetes and treatment with either anakinra, an IL-1 receptor antagonist, or anti IL-1β 282 
antibodies improves beta cell function, improves glycemic control and reduces inflammation 283 
(38–40).  Moreover, IL-1β antagonism protects against the deleterious effects of AngII on islet 284 
function in HFD fed mice (11). Thus inflammation is a key mediator of AngII-induced beta 285 
cell dysfunction (11). A role for ER stress in AngII-mediated inflammation has recently been 286 
shown in other cell types/tissues (41–43), yet the mechanism by which this occurs had not been 287 
fully explored.  288 
In this study we demonstrate that AngII-stimulated increase in pro-inflammatory cytokine 289 
expression in islets and beta cells is caused by ER stress as: 1) Il-1β and Tnf-α expression is 290 
inhibited by TUDCA; 2) Il-1β expression is inhibited by inhibition/reduced expression of 291 
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PERK and IRE1α/XBP1 ; 3) ER stress precedes an increase in the expression of Il-1β and Tnf-292 
α and; 4) thapsigargin increases the expression of Il-1β and Tnf-α. This ER stress-induced 293 
increase in cytokine expression may be mediated by TXNIP promoted by the activation of 294 
PERK and IRE1α as: 1) pharmacologically induced ER stress increases Il-1β mRNA 295 
expression through an increase in TXNIP expression, stimulated by the activation of PERK 296 
and IRE1 (16,44); 2)  AngII increases Txnip expression via a PERK- and IRE1α- dependent 297 
mechanism (Fig. 3) and; 3) Txnip precedes the expression of Tnf-α and Il-1β and is inhibited 298 
by TUDCA AngII induced ER stress is prevented by IP3R inhibition (Fig. 4). Intriguingly, 299 
inhibitors of NOX or the IP3R inhibit AngII-induced ER stress.As ER calcium depletion is 300 
known to cause ER stress (26,45–48) and ROS can potentiate IP3-dependent calcium release 301 
(36), ER calcium depletion is the likely cause of AngII-induced ER stress.  302 
We show that chronic AngII treatment causes a decrease in beta cell function both in vitro and 303 
in vivo as evaluated by a loss of GSIS caused by an increase in the release of insulin at a lower 304 
threshold of glucose (Fig. 1 and 5). Similar results have been observed in rodent and human 305 
islets chronically treated with AngII and in HFD fed mice infused with AngII (11). 306 
Interestingly, the loss of GSIS observed in this study was associated with decreased 307 
glucokinase expression (Fig. 1 and 6), a protein which sets the threshold for GSIS (49,50). As 308 
the expression of glucokinase and GLUT2 are positively related to the state of differentiation 309 
of the beta cells and their expression is stimulated by PDX1 (51–53), it is surprising that AngII 310 
increases Pdx1 and Glut2 expression both in vitro and in vivo (Fig. 1 and 6). However, we 311 
detected no change in PDX1 protein expression (results not shown). Thus the significance of 312 
these changes in mRNA expression are unclear.  313 
The components of the RAS system are expressed in islets and these are up-regulated in animal 314 
models of diabetes. Thus locally generated AngII rather than systemic AngII likely play an 315 
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important role in islet inflammation and ultimately beta cell dysfunction in type-2 diabetes 316 
(7,9,54). Interestingly, the AT1R antagonist losartan reduces high glucose induced ER stress 317 
and decreased beta cell function in human islets (55). Moreover, the administration of losartan 318 
to db/db mice improves islet function and mass, delays the onset of diabetes yet, has no effect 319 
on insulin sensitivity (7). Thus high glucose induced ER stress and beta cell dysfunction is, at 320 
least in part, mediated by AngII acting via the AT1R. Interestingly, we found that high glucose 321 
potentiated the effects of AngII on ER stress in MIN6 cells and murine islets. In addition, AngII 322 
exacerbates palmitate-induced ER stress in MIN6 cells (unpublished results). Therefore 323 
hyperglyceamia and/or obesity may potentiate the deleterious effect of increased local AngII 324 
on beta cell function by exacerbating ER stress.   325 
Together, these findings provide evidence that ER stress is a critical link between AngII and 326 
the induction of pro-inflammatory cytokines and that this may represent an initiating and/or 327 
early step in the development of beta cell dysfunction in type-2 diabetes.    328 
 329 
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 506 
Figure legends 507 
Figure 1. Angiotensin II evokes ER stress and impairs beta cell function in mouse islets 508 
of Langerhans. Mouse islets of Langerhans were treated with AngII (1μmol/l) (AngII) in the 509 
absence or presence of TUDCA (500 μg/ml) (AngII plus TUDCA = A+T) for 4 days prior to: 510 
(a) performing a GSIS assay to determine (b) the stimulatory index or (c-e) qPCR analyses of: 511 
(c) markers of beta cell function (glucokinase (Gk); Glut2 and Pdx1); (d) pro-inflammatory 512 
cytokines (Il-1β, Tnf-α, and Mcp-1);(e) markers of ER stress (BiP, Xbp1s, Ero1l, Fkbp11, 513 
Edem, Atf4, Chop,); The results are expressed as the mean +/- S.E.M of three independent 514 
experiments. * p<0.05, ** p<0.01 vs control; †† p<0.01 for the compared groups. 515 
 516 
Figure 2. ER stress precedes the expression of pro-inflammatory cytokines. MIN6 cells 517 
were treated for up to 96 h with 1μmol/l AngII. (a) Western-blot analysis of BiP, ATF4, CHOP 518 
and the phosphorylated form of IRE1α (p-IRE1), PERK (p-PERK) and eIF2α (p-eIF2α). 519 
23 
 
GAPDH was used as a loading control. Densitometric analyses of the results are presented 520 
below. qPCR analyses of: (b) markers of ER stress (Xbp1s, Chop, Tnxip) and; (c) pro-521 
inflammatory cytokines (Il-1β, Tnf-α and Mcp-1). (d) Mouse islets were treated for up to 42 h 522 
with 1μmol/l AngII. qPCR analyses of markers of ER stress (Xbp1s, Atf4, Chop, Tnxip) and 523 
pro-inflammatory cytokines (Il-1β and Tnf-α). The results are expressed as mean +/- S.E.M of 524 
four independent experiments. * p<0.05, ** p<0.01 vs control.  525 
 526 
Figure 3. Role of PERK and IRE1 in Angiotensin II induced expression of Il-1β. MIN6 527 
cells were treated with 1µmol/l AngII for 6 h in the presence or absence of vehicle (DMSO), 528 
0.5 μmol/l GSK2606414 (PERKi) (a) Western-blot analysis of BiP, ATF4, CHOP phospho-529 
IRE1α (p-IRE1α), phospho-PERK (p-PERK) and phospho-eIF2α (p-eIF2α). GAPDH was 530 
used as a loading control. Densitometric analyses of the results are presented below. (b) qPCR 531 
analyses of Txnip, Il-1β and Xbp1s. The results are expressed as mean +/- S.E.M of three 532 
independent experiments. * p<0.05, ** p<0.01 vs their control; ♦♦ p<0.01 vs the control group 533 
of siCon. MIN6 cells were transfected with control siRNA or siRNA against Ire or Xbp. 96 h 534 
post transfection cells were treated with 1µmol/l AngII for 6 h prior to qPCR analyses of (c) 535 
Xbp1s, Ire1α and (d) Txnip, and Il-1β. 536 
 537 
Figure 4. IP3R and NOX activation is required for angiotensin II induced ER stress. (a) 538 
MIN6 cells were treated with 1µmol/l AngII for 2 or 6 h in the presence of 2-539 
aminoethoxydiphenyl borate (2APB) or xestospongin-C (XestC) (10µmol/l). Western-blot 540 
analysis of BiP, ATF4, CHOP, phospho-IRE1α (p-IRE1α) and phospho-eIF2α (p-eIF2α). 541 
GAPDH was used as a loading control. Densitometric analyses of the results are presented 542 
below. The results are expressed as mean +/- S.E.M of three independent experiments. * 543 
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p<0.05, ** p<0.01 vs control; # p<0.05 for the compared groups. (b) MIN6 were treated with 544 
1µmol/l AngII for 6 h in the presence or absence of: 100 nmol/l irbesartan (IRB); 1 (+), 10 (++) 545 
or 300 μmol/l (+++) apocycin (Apo) or; 10 μmol/l diphenyleneiodonium (DPI). Superoxide 546 
levels were measured using L-012 enhanced chemiluminescence. The results are expressed as 547 
mean +/- S.E.M (NS (not significant)), ** p<0.01, * p<0.05; vs AngII treated and †† p<0.01 548 
vs control). (c) Representitive western-blot of BiP, ATF4, CHOP, phospho-IRE1and phospho-549 
eIF2α. GAPDH was used as a loading control. DPI and Apo used was 10 μmol/l.  550 
 551 
Figure 5. Angiotensin II infusion in mice causes beta cell dysfunction, ER stress and and 552 
increase in the expression of pro-inflammatory cytokines. C57BL/6J male mice were 553 
infused with AngII (at 416ng.kg-1.min-1) for 2 weeks. Where indicated TUDCA (150 mg.kg-554 
1.day-1) was also administered (Sham ( ), AngII ( ), AngII plus TUDCA (A+T) / ( )).(a) 555 
A GTT was conducted after 2 weeks of infusion and (b) the incremental area under the curve 556 
(iAUC) and (c) plasma insulin levels determined. (d) Disposition index is expressed as median 557 
+/- interquartile range. The results are expressed as mean +/- S.E.M. with eight mice per group 558 
unless otherwise stated. * p<0.05, ** p<0.01 vs sham; †† p<0.01 vs AngII. Pancreatic islets 559 
were then isolated and mRNA expression of:(e) markers of ER stress; (f) pro-inflammatory 560 
cytokines and; (g) genes related to beta cell function were determined by qPCR analysis. The 561 
results are expressed as mean +/- S.E.M. with four mice per group. * p<0.05, ** p<0.01 vs 562 
control; † p<0.05, †† p<0.01 for the compared groups.  563 
 564 
Figure 7. Schematic showing how angiotensin II causes inflammation in beta cells. AngII 565 
binds to the AT1R resulting in the activation of Gαq/PLCβ and NOX. This increases the 566 
production of ROS and IP3. ROS possibly sensitizes the IP3R for subsequent IP3-dependent 567 
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calcium release from the ER. This causes ER stress and the activation of the UPR, which 568 
promotes an increase in the expression of pro-inflammatory cytokines. 569 
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